Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week
The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.
While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.
How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), and Novavax (NASDAQ: NVAX) all vaulted higher. Here's why these three biopharmaceutical stocks ought to continue to their march northward next week and beyond.
Source Fool.com
